Kura Oncology, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology therapies and related diagnostics. The filing covers the quarter and nine months ended September 30, 2017, filed November 7, 2017. The company had no approved products and no product sales revenue.
- Tipifarnib: Phase 2 trials in HRAS-mutant head and neck squamous cell carcinoma, peripheral T-cell lymphoma, myelodysplastic syndromes, and chronic myelomonocytic leukemia.
- KO-947: Phase 1 trial of an ERK inhibitor in advanced or metastatic non-hematologic malignancies.
- KO-539: Preclinical menin-MLL program; nominated as a development candidate in December 2016.
Financial Condition and Key Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Research and development expense | $7.1 million in 2017; $5.3 million in 2016 | $18.3 million in 2017; $14.9 million in 2016 |
| General and administrative expense | $2.4 million in 2017; $1.7 million in 2016 | $6.8 million in 2017; $6.0 million in 2016 |
| Net loss | $9.3 million in 2017; $6.9 million in 2016 | $24.7 million in 2017; $20.2 million in 2016 |
| Net loss per share | $0.38 in 2017; $0.37 in 2016 | $1.16 in 2017; $1.09 in 2016 |
| Net cash used in operating activities | Not separately provided | $21.0 million in 2017; $18.6 million in 2016 |
- Liquidity: Cash, cash equivalents, and short-term investments totaled $100.8 million at September 30, 2017, consisting of $23.3 million of cash and cash equivalents and $77.5 million of short-term investments.
- Accumulated deficit: $78.5 million at September 30, 2017.
- Debt: Term loan principal was $7.5 million, with $7.0 million recorded net of discount. The debt bears interest at 8.50% as of September 30, 2017, matures November 1, 2020, and is interest-only through May 1, 2018.
- Cash flows: Investing activities used $19.3 million, primarily reflecting purchases of marketable securities. Financing activities provided $53.9 million, primarily from the August public offering.
- Share-based compensation: $3.1 million for the first nine months of 2017, compared with $1.5 million in the prior-year period.
- Margins and revenue: Operating and profit margins are not meaningful because the company generated no product revenue and incurred operating losses.
Material Changes Versus the Prior Comparable Period
- Nine-month net loss increased by $4.5 million, or approximately 22%, to $24.7 million.
- Nine-month research and development expense increased $3.4 million, driven primarily by higher tipifarnib clinical development, companion diagnostic, personnel, and share-based compensation costs.
- Nine-month general and administrative expense increased $0.8 million, mainly due to higher personnel and share-based compensation costs.
- Operating cash burn increased $2.4 million to $21.0 million.
- The company completed an August 2017 public offering of 8.805 million shares at $6.50 per share, generating approximately $53.5 million in net proceeds.
- Cash and short-term investments increased from $67.8 million at December 31, 2016 to $100.8 million at September 30, 2017.
- Related-party research and development expense declined to $1.1 million for the first nine months of 2017 from $3.1 million in the prior-year period, while company-funded internal and external development activities increased.
Guidance, Outlook, Risks, and Unusual Items
- Management believes existing cash, cash equivalents, and short-term investments will fund current operations for at least the next 12 months, but expects to require substantial additional financing to continue operations and advance its pipeline.
- Management expects research and development and general and administrative expenses to increase as clinical development and regulatory activities expand.
- The company planned to continue enrolling HRAS-mutant head and neck cancer patients, seek FDA feedback on tipifarnib registration requirements, and initiate the required clinical program in 2018.
- Management expected preliminary CMML data in December 2017, additional CMML data in 2018, and data from the PTCL, MDS, and KO-947 programs in 2018.
- In September 2017, the tipifarnib Phase 2 trial in HRAS-mutant head and neck cancer achieved its response-rate endpoint before enrollment was complete: four confirmed partial responses and two cases of stable disease were observed among the first six evaluable patients. The filing cautions that early results may not predict later-stage outcomes.
- The draw period for the additional $12.5 million Term B loan expired October 31, 2017 without a draw. The company owed an unused fee of approximately $0.3 million on November 1, 2017.
- Key risks include clinical-trial failure or delay, patient-enrollment difficulties for genetically defined cancers, safety or tolerability issues, regulatory non-approval, dependence on third-party manufacturers and clinical research organizations, companion diagnostic development, limited patent protection for tipifarnib, competition, and the need for additional capital.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of September 30, 2017.
Important Facts for Investors to Verify
- Whether early tipifarnib response data are sustained as enrollment expands and whether regulators accept the proposed registration pathway.
- The timing, design, enrollment, safety, and efficacy results of the tipifarnib, KO-947, and future KO-539 clinical programs.
- The company’s quarterly operating cash burn and the resulting timing and terms of any future equity, debt, collaboration, or licensing financing.
- The remaining debt repayment schedule, covenants, security interests, interest expense, final payment obligation, and unused-loan fee.
- The development and regulatory status of companion diagnostics, particularly for HRAS-mutant head and neck cancer.
- The scope and enforceability of intellectual-property protection, including the limited remaining protection for tipifarnib following expiration of composition-of-matter patents.